StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) company profile

RDHLNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35−0.01 (-2.91%)

Close on Nov 17, 2026Market cap $1.78MP/E –Yield –

About RedHill Biopharma

Pharmaceutical Preparations, SIC 2834

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of pharmaceuticals for gastrointestinal diseases, infectious diseases, and oncology. The company commercializes Talicia, an FDA-approved delayed-release oral capsule indicated for the treatment of Helicobacter pylori infection in adults. It also develops a clinical-stage pipeline of therapeutic candidates, including opaganib and RHB-107, addressing viral infections, inflammatory conditions, and various cancers for adult patients and global healthcare markets.

The company conducts commercial activities primarily in the United States and has out-licensed products across international markets, including the United Arab Emirates and other Gulf Cooperation Council territories. Its U.S. commercial operations operate out of Raleigh, North Carolina, and had two employees as of year-end 2025. RedHill Biopharma Ltd. maintains its corporate headquarters and principal executive offices in Tel-Aviv, Israel.

Summary of the business section of RedHill Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
RedHill Biopharma Ltd.
Founded
2009
Headquarters
Tel Aviv, L3
Address
21 Ha'Arba'A Street 64739
Phone
972-3-541-3131
Employees
13, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L3
Auditor
Kesselman & Kesselman, Tel-Aviv, Israel

Stock & identifiers

Ticker
RDHL
Exchange
Nasdaq
IPO date
Jan 7, 2013
Shares outstanding
50.92B, Dec 31, 2025
Filer category
Non-accelerated filer
Stock splits
1-for-25 reverse, Aug 20, 2024; 1-for-40 reverse, Mar 23, 2023
SEC CIK
1553846
CUSIP
757468301
ISIN
US7574683014
FIGI
BBG003RY91S7
Share class FIGI
BBG003RY92J5
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Dror Ben-AsherChief Executive Officer, Director441,350,000
Rick D. ScruggsChief Commercial Officer, Director312,500,000
Gilead RadayChief Operating Officer176,910,000
Adi FrishChief Corp & BD Officer276,810,000
Guy Joel GoldbergChief Business Officer305,720,000
Razi IngberChief Financial Officer277,560,000
Ofer TsimchiDirector146,250,000
Kenneth ReedDirector105,200,000
Shmuel CabillyDirector105,200,000
Roni MamlukDirector103,500,000

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 13 employees, of which 11 provide services in Israel and 2 provide services in the U.S.”

See a number that looks wrong?